만성 통증 치료제 시장 : 시장 규모, 점유율, 성장률, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of chronic pain drugs Market

The global chronic pain drugs market is witnessing steady growth due to the increasing prevalence of long-term pain conditions, rising geriatric population, and growing demand for safer pain management therapies. Chronic pain affects millions of patients worldwide suffering from musculoskeletal disorders, neuropathic pain, cancer-related pain, migraine, and post-surgical pain. Pharmaceutical companies are actively investing in innovative non-opioid therapies and targeted treatment approaches to address unmet patient needs.

Market Size and Market Value

The global chronic pain drugs market was valued at USD 52.50 billion in 2025 and is projected to reach USD 54.60 billion in 2026. The market is further expected to grow to USD 74.80 billion by 2034, driven by increasing chronic pain prevalence and continuous advancements in pain management therapies.

Year Market Value (USD Billion)

2025 52.50

2026 54.60

2034 74.80

North America dominated the global market in 2025, accounting for 34.0% of total revenue due to high diagnosis rates, advanced healthcare infrastructure, and strong adoption of innovative pain medications.

Key Market Trends

One of the most significant trends shaping the chronic pain drugs market is the growing shift toward non-opioid pain management therapies. Concerns regarding opioid addiction, misuse, and long-term safety risks have encouraged healthcare providers and pharmaceutical companies to focus on safer alternatives.

In January 2025, Vertex Pharmaceuticals received FDA approval for JOURNAVX (suzetrigine), a non-opioid treatment for moderate-to-severe acute pain. Such developments highlight the industry's transition toward targeted and addiction-free pain management solutions.

Market Drivers

Growing Aging Population Increasing Demand for Pain Management

The expanding elderly population is a major growth driver for the chronic pain drugs market. Older adults are more vulnerable to osteoarthritis, lower back pain, neuropathic disorders, and other chronic conditions requiring long-term treatment.

According to WHO estimates published in 2025, the global population aged 60 years and above is expected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. The increasing burden of chronic pain among aging individuals continues to support market expansion.

Market Restraints

Regulatory Concerns Regarding Opioid Usage

Long-term opioid use remains associated with addiction, overdose, and dependency risks. Regulatory agencies are implementing stricter prescribing guidelines, limiting the growth potential of opioid-based therapies.

In July 2025, the U.S. FDA strengthened safety warnings for opioid pain medications after reviewing evidence related to misuse, opioid use disorder, and overdose risks.

Market Opportunities

Personalized and Indication-Specific Therapies

Healthcare providers are increasingly adopting personalized pain management approaches tailored to specific disease conditions. This trend is creating opportunities for targeted therapies designed for neuropathic pain, osteoarthritis, and post-surgical pain.

In May 2025, TRemedical initiated a Phase II trial of TRD205 for chronic post-surgical neuropathic pain, demonstrating growing interest in indication-specific treatment solutions.

Market Challenges

Long-Term Safety Concerns Associated with NSAIDs

Although NSAIDs remain widely used in chronic pain management, long-term usage may increase the risk of cardiovascular complications, including heart attack and stroke. These concerns encourage the development of safer alternative therapies.

Segment Analysis

By Drug Class

The NSAIDs segment dominated the market in 2025 due to widespread use in osteoarthritis, joint pain, and musculoskeletal disorders. Their affordability and broad clinical utility continue to drive demand.

The cannabinoid-based drugs segment is expected to witness the fastest growth due to increasing research and acceptance of alternative pain therapies.

By Disease Indication

The musculoskeletal pain segment held the largest market share in 2025. Conditions such as osteoarthritis, chronic back pain, and neck pain continue to generate significant demand for pain management medications.

By Age Group

The adult segment accounted for the largest share owing to the high prevalence of chronic pain among working-age and elderly populations.

By Product Type

Generic drugs dominated the market because they offer cost-effective treatment options for long-term therapy.

By Route of Administration

The oral segment led the market due to convenience, ease of administration, and suitability for long-term outpatient treatment.

By Distribution Channel

Drug stores and retail pharmacies remained the leading distribution channel owing to easy patient access and strong prescription refill volumes.

Regional Analysis

North America

North America generated USD 17.85 billion in 2025, maintaining its leadership position due to advanced healthcare systems, large patient populations, and strong adoption of innovative therapies.

Europe

Europe continues to experience steady growth driven by an aging population and increasing prevalence of chronic pain disorders.

Asia Pacific

Asia Pacific is emerging as a significant growth region due to rapid population aging, improving healthcare access, and increasing awareness of chronic pain management.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth supported by healthcare infrastructure development and growing diagnosis rates.

Competitive Landscape

The market remains fragmented, with major players focusing on acquisitions, product launches, strategic partnerships, and research investments.

Key companies operating in the market include:

• Viatris Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Lundbeck A/S
• Grunenthal GmbH

In May 2025, Eli Lilly acquired SiteOne Therapeutics to strengthen its non-opioid pain treatment pipeline, highlighting the industry's focus on next-generation pain therapies.

Conclusion

The chronic pain drugs market is expected to witness sustained growth between 2025 and 2034, supported by rising chronic pain prevalence, an expanding geriatric population, and increasing demand for safer non-opioid treatment options. While regulatory scrutiny around opioids and safety concerns related to NSAIDs remain challenges, ongoing innovation in personalized medicine, targeted therapies, and non-addictive pain management solutions is creating significant growth opportunities. With market value projected to increase from USD 52.50 billion in 2025 to USD 74.80 billion by 2034, the industry is poised for continued expansion as pharmaceutical companies invest heavily in advanced chronic pain treatment technologies.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * NSAIDs

• Opioids
• Antidepressants
• Anticonvulsants / Gabapentinoids
• Topical Analgesics
• Local Anesthetics
• Cannabinoid-based Drugs
• NMDA Receptor Antagonists

By Disease Indication * Musculoskeletal Pain

• Neuropathic Pain
• Cancer-related Pain
• Postsurgical / Post-traumatic Pain
• Visceral Pain
• Headache / Orofacial Pain
• Primary Pain Syndromes
• Others

By Age Group * Pediatric

• Adults

By Type * Branded

• Generic

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Others

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Region
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Regulatory Scenario, By Key Countries/Regions
• 4.5. Key Start Up, By Key Regions, 2025

5. Global Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. NSAIDs
  • 5.1.2. Opioids
  • 5.1.3. Antidepressants
  • 5.1.4. Anticonvulsants / Gabapentinoids
  • 5.1.5. Topical Analgesics
  • 5.1.6. Local Anesthetics
  • 5.1.7. Cannabinoid-based Drugs
  • 5.1.8. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Musculoskeletal Pain
  • 5.2.2. Neuropathic Pain
  • 5.2.3. Cancer-related Pain
  • 5.2.4. Postsurgical / Post-traumatic Pain
  • 5.2.5. Visceral Pain
  • 5.2.6. Headache / Orofacial Pain
  • 5.2.7. Primary Pain Syndromes
  • 5.2.8. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adult
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generic
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Oral
  • 5.5.2. Parenteral
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Speciality Pharmacies
  • 5.6.3. Drug Stores & Retail Pharmacies
  • 5.6.4. Online Pharmacies
  • 5.6.5. Others
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. NSAIDs
  • 6.1.2. Opioids
  • 6.1.3. Antidepressants
  • 6.1.4. Anticonvulsants / Gabapentinoids
  • 6.1.5. Topical Analgesics
  • 6.1.6. Local Anesthetics
  • 6.1.7. Cannabinoid-based Drugs
  • 6.1.8. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Musculoskeletal Pain
  • 6.2.2. Neuropathic Pain
  • 6.2.3. Cancer-related Pain
  • 6.2.4. Postsurgical / Post-traumatic Pain
  • 6.2.5. Visceral Pain
  • 6.2.6. Headache / Orofacial Pain
  • 6.2.7. Primary Pain Syndromes
  • 6.2.8. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adult
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generic
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Oral
  • 6.5.2. Parenteral
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Drug Stores & Retail Pharmacies
  • 6.6.3. Speciality Pharmacies
  • 6.6.4. Online Pharmacies
  • 6.6.5. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. NSAIDs
  • 7.1.2. Opioids
  • 7.1.3. Antidepressants
  • 7.1.4. Anticonvulsants / Gabapentinoids
  • 7.1.5. Topical Analgesics
  • 7.1.6. Local Anesthetics
  • 7.1.7. Cannabinoid-based Drugs
  • 7.1.8. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Musculoskeletal Pain
  • 7.2.2. Neuropathic Pain
  • 7.2.3. Cancer-related Pain
  • 7.2.4. Postsurgical / Post-traumatic Pain
  • 7.2.5. Visceral Pain
  • 7.2.6. Headache / Orofacial Pain
  • 7.2.7. Primary Pain Syndromes
  • 7.2.8. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adult
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generic
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Oral
  • 7.5.2. Parenteral
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Drug Stores & Retail Pharmacies
  • 7.6.3. Speciality Pharmacies
  • 7.6.4. Online Pharmacies
  • 7.6.5. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. NSAIDs
  • 8.1.2. Opioids
  • 8.1.3. Antidepressants
  • 8.1.4. Anticonvulsants / Gabapentinoids
  • 8.1.5. Topical Analgesics
  • 8.1.6. Local Anesthetics
  • 8.1.7. Cannabinoid-based Drugs
  • 8.1.8. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Musculoskeletal Pain
  • 8.2.2. Neuropathic Pain
  • 8.2.3. Cancer-related Pain
  • 8.2.4. Postsurgical / Post-traumatic Pain
  • 8.2.5. Visceral Pain
  • 8.2.6. Headache / Orofacial Pain
  • 8.2.7. Primary Pain Syndromes
  • 8.2.8. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adult
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generic
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Oral
  • 8.5.2. Parenteral
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Drug Stores & Retail Pharmacies
  • 8.6.3. Speciality Pharmacies
  • 8.6.4. Online Pharmacies
  • 8.6.5. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. NSAIDs
  • 9.1.2. Opioids
  • 9.1.3. Antidepressants
  • 9.1.4. Anticonvulsants / Gabapentinoids
  • 9.1.5. Topical Analgesics
  • 9.1.6. Local Anesthetics
  • 9.1.7. Cannabinoid-based Drugs
  • 9.1.8. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Musculoskeletal Pain
  • 9.2.2. Neuropathic Pain
  • 9.2.3. Cancer-related Pain
  • 9.2.4. Postsurgical / Post-traumatic Pain
  • 9.2.5. Visceral Pain
  • 9.2.6. Headache / Orofacial Pain
  • 9.2.7. Primary Pain Syndromes
  • 9.2.8. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adult
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generic
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Oral
  • 9.5.2. Parenteral
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Drug Stores & Retail Pharmacies
  • 9.6.3. Speciality Pharmacies
  • 9.6.4. Online Pharmacies
  • 9.6.5. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Chronic Pain Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. NSAIDs
  • 10.1.2. Opioids
  • 10.1.3. Antidepressants
  • 10.1.4. Anticonvulsants / Gabapentinoids
  • 10.1.5. Topical Analgesics
  • 10.1.6. Local Anesthetics
  • 10.1.7. Cannabinoid-based Drugs
  • 10.1.8. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Musculoskeletal Pain
  • 10.2.2. Neuropathic Pain
  • 10.2.3. Cancer-related Pain
  • 10.2.4. Postsurgical / Post-traumatic Pain
  • 10.2.5. Visceral Pain
  • 10.2.6. Headache / Orofacial Pain
  • 10.2.7. Primary Pain Syndromes
  • 10.2.8. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adult
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generic
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Oral
  • 10.5.2. Parenteral
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Drug Stores & Retail Pharmacies
  • 10.6.3. Speciality Pharmacies
  • 10.6.4. Online Pharmacies
  • 10.6.5. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Viatris Inc.
  • 11.2.2. Eli Lilly and Company
  • 11.2.3. AbbVie Inc.
  • 11.2.4. Teva Pharmaceutical Industries Ltd.
  • 11.2.5. Amgen Inc.
  • 11.2.6. H. Lundbeck A/S
  • 11.2.7. Grunenthal GmbH
  • 11.2.8. Collegium Pharmaceutical, Inc.
  • 11.2.9. Haleon plc
  • 11.2.10. Kenvue Inc.